人工智能在数字病理学中常规临床应用的路线图
该文由NCRI细胞分子病理(CM-Path)倡议与英国体外诊断协会(BIVDA)联合提出,旨在为学术界、产业界和临床医生开发图像分析与机器学习软件工具提供一条通往获批临床使用的路线图,以应对数字病理革命中软件工具激增但缺乏稳健循证框架的问题。
要点
- 人工智能将推动图像分析与机器学习整合进常规组织病理学。
- 数字病理革命催生了大量图像分析软件工具,但缺乏循证开发框架。
- CM-Path与BIVDA提出协作开发路线图,以助软件工具达到获批临床使用。
核心结论
- 需要建立稳健且基于证据的框架,以协作方式开发图像分析软件工具并满足监管批准。
研究设计与样本
- 由NCRI细胞分子病理(CM-Path)倡议与英国体外诊断协会(BIVDA)联合提出路线图。
主要发现
- 数字革命正在改变诊断组织病理学的报告实践,并引发图像分析软件工具的激增。
- 该发展可能发现新的预测性临床信息,并有望应对国际病理学劳动力短缺。
临床怎么用
- 学术界、产业界和临床医生可依据该路线图协作开发新软件工具,直至获批临床使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The use of artificial intelligence will transform clinical practice over the next decade and the early impact of this will likely be the integration of image analysis and machine learning into routine histopathology. In the UK and around the world, a digital revolution is transforming the reporting practice of diagnostic histopathology and this has sparked a proliferation of image analysis software tools. While this is an exciting development that could discover novel predictive clinical information and potentially address international pathology workforce shortages, there is a clear need for a robust and evidence-based framework in which to develop these new tools in a collaborative manner that meets regulatory approval. With these issues in mind, the NCRI Cellular Molecular Pathology (CM-Path) initiative and the British In Vitro Diagnostics Association (BIVDA) have set out a roadmap to help academia, industry, and clinicians develop new software tools to the point of approved clinical use. © 2019 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
引用
- Colling R, Pitman H, Oien K, et al. Artificial intelligence in digital pathology: a roadmap to routine use in clinical practice. J Pathol. 2019. PMID: 31144302. doi:10.1002/path.5310
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。